Axon Enterprise, Inc $AXON Shares Sold by Central Pacific Bank Trust Division

Key Points

• Central Pacific Bank Trust Division slashed its stake in Axon by 98.3% in Q4, selling 76,821 shares and now holding 1,356 shares valued at $770,000.
• Axon posted a strong quarter, beating estimates with $2.15 EPS vs $1.60 and revenue of $796.72 million (up 38.5% year‑over‑year), underscoring its subscription/software growth momentum.
• Insiders sold a total of 23,855 shares worth $13.3 million last quarter, even as analysts remain broadly positive (average rating "Moderate Buy" and average target ≈ $762.93).

Central Pacific Bank Trust Division cut its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 98.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,356 shares of the biotechnology company's stock after selling 76,821 shares during the period. Central Pacific Bank Trust Division's holdings in Axon Enterprise were worth $770,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after buying an additional 376,904 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company's stock worth $677,412,000 after buying an additional 330,213 shares during the period. Vestor Capital LLC grew its holdings in shares of Axon Enterprise by 438,636.3% during the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company's stock valued at $690,170,000 after buying an additional 833,409 shares during the last quarter. Norges Bank purchased a new stake in shares of Axon Enterprise during the second quarter valued at $637,806,000. Finally, Northern Trust Corp increased its position in shares of Axon Enterprise by 1.6% in the 3rd quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company's stock valued at $533,871,000 after acquiring an additional 11,726 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Down 1.2%

Shares of Axon Enterprise stock opened at $496.12 on Friday. The stock has a market cap of $39.89 billion, a PE ratio of 326.39, a price-to-earnings-growth ratio of 10.59 and a beta of 1.46. The firm has a fifty day moving average price of $519.47 and a 200 day moving average price of $600.33. Axon Enterprise, Inc has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm's revenue was up 38.5% on a year-over-year basis. During the same period in the prior year, the company earned $2.08 earnings per share. Equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AXON. Needham & Company LLC reduced their target price on Axon Enterprise from $870.00 to $600.00 and set a "buy" rating for the company in a research note on Friday, February 20th. Citigroup reiterated a "buy" rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Wall Street Zen upgraded Axon Enterprise from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. Finally, Piper Sandler dropped their target price on Axon Enterprise from $753.00 to $690.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $762.93.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Software & Services momentum supports a higher-margin recurring revenue outlook—analyst write-ups highlight ~38% revenue growth and continued subscription expansion, which underpins long-term upside. Read More.
• Positive Sentiment: Earnings beat: Axon’s Feb. quarter topped estimates on EPS and revenue (revenue up ~38.5% YoY), reinforcing the growth narrative that many investors cite when valuing the stock. Read More.
• Positive Sentiment: Municipal procurement continues to drive hardware + software adoption—local grants (e.g., Decatur, IL) are cited as examples of steady demand for public-safety tech. Read More.
• Positive Sentiment: Institutional/coverage interest (features mentioning funds and “trending” status) can attract flows and boost liquidity, supporting the stock over time. Read More.
• Neutral Sentiment: Aggregator/“trending” articles raise awareness but are not direct fundamental catalysts; useful for retail/institutional interest but don’t change cash flows immediately. Read More.
• Neutral Sentiment: Short-interest data being reported as “0 shares” with NaN changes reads like a reporting error—treat as noise until exchanges/brokers clarify; not an actionable signal now.
• Negative Sentiment: Insider selling: Director Erika Nardini sold 198 shares (~$506.58 avg) and Director Jeri Williams sold 157 shares (~$490 avg) in mid‑March; while small in absolute dollars, these filings can dent sentiment. Read More. Read More.
• Negative Sentiment: Near-term skepticism: critical pieces noting a multi‑day losing streak and a sizable short-term market‑cap decline are amplifying caution and likely contributing to today’s pullback. Read More.

Insiders Place Their Bets

In related news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the transaction, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Erika Nardini sold 198 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the transaction, the director directly owned 1,946 shares of the company's stock, valued at $985,804.68. The trade was a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 23,855 shares of company stock worth $13,299,928. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.